U.S. markets closed

Vanda Pharmaceuticals Inc. (VNDA)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
4.1100+0.2200 (+5.66%)
Al cierre: 04:00PM EDT
4.1800 +0.07 (+1.70%)
Fuera de horario: 07:55PM EDT

Vanda Pharmaceuticals Inc.

2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
202 734 3400
https://www.vandapharma.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo203

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Mihael H. Polymeropoulos M.D.Founder, President, CEO & Chairman of The Board1.51M1.12M1960
Mr. Kevin Patrick MoranSenior VP, CFO & Treasurer660.22k56.15k1985
Mr. Timothy WilliamsSenior VP, General Counsel & Secretary724.38kN/D1976
Mr. Joakim WijkstromSenior VP & Chief Marketing Officer836.36kN/D1966
Mr. Gunther BirznieksSenior Vice President of Business Development690.83k9.25k1970
Mr. Scott L. HowellChief People OfficerN/DN/DN/D
Ms. Elizabeth Van EveryHead of Corporate AffairsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Gestión corporativa

La calificación ISS Governance QuickScore de Vanda Pharmaceuticals Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 3; Junta: 6; Derechos del accionista: 5; Compensación: 5.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.